Erasca, Inc. has successfully closed an upsized public offering of 25,875,000 shares of its common stock, generating approximately $258.8 million in gross proceeds. The company plans to use these funds for research and development of its product candidates and other programs. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI acted as joint book-running managers. Erasca is a precision oncology company dedicated to developing therapies for RAS/MAPK pathway-driven cancers, with a mission to erase cancer. The company cautions that forward-looking statements may be subject to risks and uncertainties. Contact Joyce Allaire for more information.

Read more at GlobeNewswire: Erasca Announces Closing of Upsized Public Offering of